Open AccessIncreased systolic blood pressure with rofecoxib in congenital furosemide-like salt loss
Author(s) -
Martin Kömhoff,
Günter Klaus,
Sofia Nazarowa,
Stephan C. Reinalter,
Hannsjörg W. Seyberth
Publication year - 2006
Publication title -
nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfl096
Subject(s) - medicine , furosemide , rofecoxib , endocrinology , blood pressure , thiazide , creatinine , fractional excretion of sodium , aldosterone , cyclooxygenase , chemistry , biochemistry , enzyme
To analyse whether congenital furosemide- or thiazide-like renal salt loss protects against the potential prohypertensive effects of two cyclooxygenase (COX) inhibitors: rofecoxib, a COX-2 selective inhibitor, and indomethacin, an unselective COX-inhibitor.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom